Company news
GB Sciences, Inc. news in 2021
GB Sciences, Inc.'s news releases, calls and decks from 2021, newest first.
Gb Sciences Targets COVID-19 Treatment as Omicron Variant Arrives
December 6, 2021
Gb Sciences Accelerates Drug Development via Innovative Biopharma Technology and Strategic Partnerships
November 29, 2021
Gb Sciences Starts Preclinical Study for Plant-Based Formulas to Treat Depression and Anxiety
November 1, 2021
Gb Sciences Achieves Positive Proof-of-Concept Results for Their Cytokine Release Syndrome Therapies Designed to Suppress COVID-Related Hyperinflammation
September 14, 2021
Gb Sciences Presenting COVID-Related Cytokine Release Syndrome Results at H.C. Wainwright's 23rd Annual Global Investment Conference
September 9, 2021
Keynotes, Educational Panels and 60 Companies to Present at the SNN Network Summer Virtual Event on August 17-19, 2021
August 15, 2021
Gb Sciences to Present at the SNN Network Summer Virtual Event on Wednesday, August 18th, 2021
August 9, 2021
GB Sciences Is Developing Plant-Inspired Mixtures for Anxiety, Depression, and Pain From PhAROS, GB Sciences' Proprietary AI-Accelerated Drug Discovery Platform
July 26, 2021
GB Sciences Using AI Technology in Plant-Based Drug Discovery Research
June 28, 2021
GB Sciences' Board of Directors Has Passed a Unanimous Written Consent Promoting Dr. Andrea Small-Howard to the Role of President
June 16, 2021
GB Sciences and Purisys Announce Preferred Supplier Relationship to Advance Cannabinoid-Containing Pharmaceuticals
April 19, 2021
GB Sciences Files Provisional Patent Application to Protect Its Proprietary Drug Discovery Platform
April 6, 2021
GB Sciences Publishes Study on Creation of Novel Terpene-Containing Nanoparticles for Pain Relief
March 22, 2021